Two-Drug Regimen Offers Better Health-Related Quality of Life in Advanced Renal Cell Carcinoma
The combination of lenvatinib and pembrolizumab improved health-related quality of life.
Kidney Cancer
Telaglenastat Fails to Improve Outcomes in Previously Treated Metastatic RCC
Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.
Combo Continues to Show Superior Efficacy vs Sunitinib in Advanced Clear Cell Renal Cell Carcinoma
Pembrolizumab plus axitinib improved progression-free and overall survival.
Pembrolizumab After RCC Surgery: Potential New Standard of Care
In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.
Understanding Adverse Effects Associated With Immune-Based Combination Therapies for Metastatic Renal Cell Carcinoma
A meta-analysis of phase 3 randomized control trials sought to identify the TRAEs associated with 7 therapeutic regimens for the treatment of mRCC.
Obesity Paradox in Renal Cell Carcinoma: Why Do Patients Who Are Obese Have Improved Survival?
A review of retrospective data sought to better understand the relationship between obesity and survival in renal cell carcinoma.
Active Surveillance Deemed “Justifiable” Option for Metastatic Renal Cell Carcinoma
For real-world patients with mRCC, active surveillance may be a worthwhile alternative to immediate systemic therapy.
Local Salvage Therapy Effective for Local, Regional Recurrence of RCC
Local surgery or ablation may be most appropriate for patients with a solitary site of locoregional recurrence following definitive surgery for clinically localized renal cell carcinoma, according to investigators.
Pembrolizumab Plus Lenvatinib Prolongs Survival in Renal Cell Carcinoma
Investigators report findings from the phase 3 CLEAR trial that assessed outcomes with pembrolizumab plus lenvatinib, lenvatinib plus everolimus, or sunitinib in treatment-naive patients with advanced renal cell carcinoma.
Factors Associated With Response to Nivolumab in Renal Cell Carcinoma
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
- Loading...
Loading...
Next post in Renal Cell Carcinoma
Loading... 
Loading...